Visual library
Browse infographics and comprehensive reviews on obesity treatments, clinical trials, and patient care.
44 resources · 12 shown
The Next Wave of Obesity Medicine: 12 Investigational Therapies
A November 2026 overview of 12 investigational obesity therapies, spanning amylin-based treatments, GLP-1/GIP pathways, glucagon-containing combinations, and GLP-1 receptor agonists.
Advancing Beyond Weight Loss: AHA Scientific Sessions 2026
Three obesity medication findings from AHA Scientific Sessions 2026: survodutide and cardiovascular safety, orforglipron and sleep apnea, and semaglutide and obesity-related heart failure.
Get to Know VK2735
A six-slide overview of VK2735, covering injectable and oral Phase 2 results, exploratory maintenance dosing, dose-specific tolerability and Phase 3 programs.
Retatrutide vs Semaglutide 2 mg
A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
Amylin: The Next Frontier in Obesity Medicine?
Explore amylin biology and clinical trial results for cagrilintide, CagriSema, petrelintide, zenagamtide (amycretin), and eloralintide in obesity medicine.
Retatrutide and Sleep Apnea: TRIUMPH-1-OSA and TRIUMPH-2-OSA
A visual summary of 80-week Phase 3 retatrutide results on apnea-hypopnea index in adults with obesity and moderate-to-severe obstructive sleep apnea, with and without type 2 diabetes.
Obesity Medicine Is Advancing. Insurance Coverage Is Moving Backward.
A visual about the widening gap between improving obesity treatments and shrinking coverage, with examples of employer and plan changes and an October 18 state-by-state Medicaid review.
CagriSema in Women: REDEFINE-1 Menopause Analyses
A visual summary of two post hoc analyses from the Phase 3 REDEFINE 1 trial reporting CagriSema weight-loss outcomes in women overall and across menopause stages.
GLP-1s & Biological Aging: What the Evidence Actually Shows
A visual look at semaglutide and tirzepatide aging research, from biological clocks to SELECT mortality and mouse lifespan, with the full LinkedIn post and study context.
GLP-1s and NAION: What the Evidence Actually Shows
A full clinical evidence review of GLP-1 based therapies and NAION, with the infographic, study-by-study findings, absolute-risk context, practical considerations, and linked references.
EASD 2026 Obesity Medicine Roundup: A Comprehensive Review of the New Data
A comprehensive EASD 2026 review of obesity medicines: clinical readouts, company-by-company molecule summaries, evidence caveats, and primary source links.
EASD 2026: 7 additional updates worth knowing
Seven additional obesity medicine updates highlighted at EASD 2026: survodutide, olatorepatide, trevogrumab, orforglipron, ABBV-295, KAI-4729, and ecnoglutide.